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Cancer cells possess fundamentally alteredmetabolism that provides a foundation to support tumorigenicity
and malignancy. Our understanding of the biochemical underpinnings of cancer has benefited from the inte-
grated utilization of large-scale profiling platforms (e.g., genomics, proteomics, and metabolomics), which,
together, can provide a global assessment of how enzymes and their parent metabolic networks become
altered in cancer to fuel tumor growth. This review presents several examples of how these integrated plat-
forms have yielded fundamental insights into dysregulated metabolism in cancer. We will also discuss ques-
tions and challenges that must be addressed to more completely describe, and eventually control, the
diverse metabolic pathways that support tumorigenesis.Introduction
Cancer cells have fundamentally altered cellular metabolism,
which directly contributes to tumorigenicity andmalignancy. De-
ciphering the full scope of dysregulated metabolism in cancer
and its relevance to disease pathogenesis and potential thera-
peutic relevance requires the advancement of technologies to
identify altered enzymes and metabolites in cancer. This review
will discuss how large-scale profiling methods, such as geno-
mics, proteomics, and metabolomics, have been innovatively
used to elucidate metabolic pathways that drive tumorigenesis
and metastasis. Not only have such large-scale endeavors
been useful in providing fundamental insights into the basic
biochemistry that defines cancer cells, but they have also led
to the discovery of potential targets for cancer therapy. We will
also discuss challenges facing the field of cancer metabolism.
Fundamental to the proliferation of a transformed cell is first
and foremost the ability to rapidly and robustly biosynthesize
essential biomolecules required for cell division. The study of
cancer metabolism has hence primarily focused on pathways
that, when altered, can lead to the aberrant production or
consumption of essential biomolecules such as glucose, amino
acids, nucleotides, and lipids (DeBerardinis et al., 2008a,
2008b). Beyond the synthesis of biomolecules, studies have
also shown that cancer cells rewire, mutationally activate, and/
or transcriptionally upregulate metabolic pathways that produce
oncogenic signaling molecules that in turn fuel tumor growth and
malignancy (Cairns et al., 2011; Dang et al., 2009; Nomura et al.,
2010a). For many of these pathways, large-scale profiling plat-
forms and innovative discovery-based approaches played crit-
ical roles in uncovering connections to cancer pathogenicity.
The Regulation of Pyruvate Kinase and Its Role in
Glucose Metabolism in Cancer
In 1929, Otto Warburg noted that transformed cells consume
glucose at an abnormally high rate (Warburg, 1956). However,
rather than leading to an increase in cellular energy via the citric
acid cycle, Warburg showed that this increased glycolytic fluxinstead leads to the production of lactate, even under nonhy-
poxic conditions (Warburg, 1956). While this ‘‘Warburg effect’’
appeared to be an irrefutable and universal property of most
cancer cells, what had remained enigmatic for some time was
the reason for and mechanism by which cancer cells adopt
this switch to aerobic glycolysis. Nearly 80 years later, critical
insights have beenmade demonstrating how cancer cells exhibit
multiple additional levels of regulation on glycolysis, which
collectively diverts carbon from glucose toward the synthesis
of molecular building blocks such as amino acids, nucleic acids,
and lipids, for the purpose of generating ample protein, DNA, and
cellular membranes for proliferation. Many of these discoveries
have beenmadewith the help of innovative large-scale genomic,
proteomic, and metabolomic profiling platforms that have al-
lowed scientists to delve deeper into aspects of cancer metabo-
lism. Christofk et al. in 2008 demonstrated that a single switch of
pyruvate kinase from theM1 (PKM1) toM2 (PKM2) splice isoform
is sufficient to shift cellular metabolism to favor aerobic glycol-
ysis (Christofk et al., 2008a). They then further showed that
PKM2-expressing cells consume less oxygen and produce
more lactate than PKM1-expressing cells and that replacement
of PKM2 with PKM1 in cancer cells quite provocatively reverses
this metabolic phenotype that embodies the Warburg effect
(Christofk et al., 2008a). Christofk et al. went further to develop
cells that stably express mouse PKM1 or PKM2 in the human
lung cancer cell line H1299 in the background of knocking
down endogenous PKM2. Quite provocatively, mice injected
with the PKM1 cells showed a significant delay in tumor develop-
ment as compared with those injected with PKM2-expressing
cells, which developed much larger tumors. These studies
showed that PKM2 expression provides a selective growth
advantage for tumor cells in vivo, prompting investigations into
the metabolic and regulatory mechanisms behind the action of
PKM2 in cancer.
Subsequent proteomic studies have uncovered that PKM2,
unlike PKM1, cannot constitutively maintain its active tetrameric
structure due to multiple additional levels of posttranslationalCell Metabolism 16, November 7, 2012 ª2012 Elsevier Inc. 565
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decreased pyruvate kinase activity (Anastasiou et al., 2011;
Christofk et al., 2008b; Hitosugi et al., 2009; Lv et al., 2011)
(Figure 1). When searching for phosphotyrosine (pTyr)-binding
proteins from cell lysates using a SILAC (stable isotope labeling
of amino acids in cell culture)-based quantitative proteomic
enrichment strategy with a phosphotyrosine peptide library
affinity matrix, Christofk et al. found that PKM2 selectively and
directly binds to phosphotyrosine peptides, resulting in the
displacement of the activating cofactor fructose-1,6-bisphos-
phate, thereby inhibiting PKM2 activity (Christofk et al., 2008b).
Christofk et al. labeled HeLa cells with heavy isotopic 13C-lysine
and 13C-arginine or normal isotopic 12C-lysine and 12C-arginine,
followed by enrichment of phosphotyrosine binding proteins by
flowing heavy cell lysates over a phosphotyrosine peptide library
versus light cell lysates over a corresponding unphosphorylated
peptide library. Upon proteomic analysis, pyruvate kinase was
among proteins that exhibited a significantly higher SILAC heavy
to light ratio (Christofk et al., 2008b) (Figure 2). The authors then
showed that a mutant form of PKM2 that can no longer bind
phosphotyrosine peptides, and thereby exhibits greater PKM2
activity, leads to enhanced oxygen consumption and decreased
lactate production, and that PKM2-expressing cells divert up-
stream glycolytic intermediates to an anabolic, rather than
catabolic, fate. In 2009, using a phosphoproteomic strategy of
enriching tyrosine-phosphorylated peptides, Hitosugi et al.
found that PKM2 is also phosphorylated by signaling conferred
by the oncogenic fibroblast growth factor receptor type 1, which
in turn also inhibits the formation of the active tetrameric form of
PKM2 by disrupting its interaction with fructose-1,6-bisphos-
phate. The authors then demonstrated that a mutant form of
PKM2 that is incapable of becoming phosphorylated leads to
lactate reduction and increased oxygen consumption—a meta-
bolic feature also observed when PKM2 is replaced with the
constitutively active PKM1 (Hitosugi et al., 2009). A recent study
has provided yet another mode of regulation upon PKM2 that
leads to a diversion of glycolytic flux. Anastasiou et al. showed
that Cys358 on PKM2 is an oxidative sensor that becomes
oxidized to inhibit PKM2 activity (Anastasiou et al., 2011). This
inhibition of PKM2 activity then leads to the buildup of glu-
cose-6-phosphate, which can subsequently get diverted to the
pentose phosphate pathway to generate sufficient antioxidant
response, via the reduction of glutathione (GSH), for the cancer
cell (Figure 1). The authors showed that a C358S mutant of
PKM2 leads to decreased GSH and increased oxidative stress,
leading to impairments in proliferation and tumor xenograft
growth (Anastasiou et al., 2011). Lv et al. recently also identified
an acetylated lysine on PKM2, using a proteomic strategy in
which the authors immunoprecipitated acetyl-lysine peptides
from tryptically digested cytosolic proteomes of LNCaP prostate
cancer cells and primary prostate tumors (Lv et al., 2011), and
analyzed eluting peptides by LC-MS/MS. The authors showed
that K305 acetylation on PKM2 is stimulated by glucose and
inhibits PKM2 activity through subsequent autophagic degrada-
tion, leading to enhanced tumorigenicity. They further showed
that mutating the lysine targeted for acetylation to an acetyla-
tion-mimic glutamine leads to enhanced proliferation and tumor
growth (Lv et al., 2011). Collectively, a variety of proteomic
approaches have been used to provide clear evidence that566 Cell Metabolism 16, November 7, 2012 ª2012 Elsevier Inc.PKM2 is subject to multiple modes of posttranslational regula-
tion that function to retard the last step of glycolysis, thereby
leading to an accumulation of upstream glycolytic intermediates.
Moreover, cancer cells can divert these upstream glycolytic
intermediates toward various anabolic processes in order to
maintain their proliferative and tumorigenic capacity.
While the effects of posttranslational regulation on the meta-
bolic functionality of PKM2 are now well understood, the mech-
anism whereby PKM2 drives tumorigenicity and the extent to
which PKM2 alters glucose metabolism in cancer cells have re-
mained enigmatic. However, recent studies showing noncata-
lytic functions of this enzyme have provided valuable insights
toward answering these unsettled questions. Yang et al. found
that epidermal growth factor receptor (EGFR) activation induces
nuclear translocation of PKM2, but not PKM1, where a lysine
residue 433 of PKM2 binds to c-Src-phosphorylated Y333 of
b-catenin (Yang et al., 2011). The authors showed that this is
a requisite step for promoter recruitment of these two proteins
to initiate cyclin D1 expression, which is fundamental to cell
proliferation and brain tumor development. Luo et al. found
that PKM2, but not PKM1, interacts directly with the HIF-1a
subunit and promotes transactivation of HIF-1 target genes
by enhancing HIF-1 binding and p300 recruitment to hypoxia
response elements (Luo et al., 2011). These authors further
showed that PKM2 interacts with prolyl hydroxylase 3 (PHD3)
to enhance PKM2 binding to HIF-1a as well as its coactivator
functions. In addition, they showed that PHD3 knockdown not
only reduces glucose uptake and lactate production but also
increases oxygen consumption. Collectively, these studies
show that the noncatalytic roles of PKM2 are also critical in re-
programming the metabolism of cancer cells and driving cell
proliferation and tumor growth.
Based on recent studies showing that activating PKM2 may
reverse the Warburg effect, valiant efforts have been made in
recent years to develop activators of PKM2 that enhance the
enzymatic activity of PKM2, toward potential cancer therapy.
These activators were identified through quantitative high-
throughput screening efforts of nearly 300,000 small molecules
of the NIH Molecular Libraries Small Molecule Repository using
an ATP-generation assay coupled to luminescence (Boxer
et al., 2010; Jiang et al., 2010; Walsh et al., 2011). These small-
molecules primarily consist of N,N0-diarylsulfonamides, thieno
[3,2-b]pyrrole[3,2-d]pyridazinones, and 2-oxo-N-aryl-1,2,3,4-
tetrahydroquinoline-6-sulfonamides. One of these small mole-
cules, DASA-10, was recently shown to enhance cancer cell
death under conditions of oxidative stress (Anastasiou et al.,
2011). While activators of PKM2 activity have the potential to
become promising therapeutic strategies for cancer, pharmaco-
logical or genetic therapies to downregulate PKM2 expression,
which would thereby impair the noncatalytic protein-protein
interactions of PKM2, may also provide unique avenues for
cancer therapy.
Aberrant Amino Acid and TCA Cycle Metabolism
Underlying Cancer
In addition to altered glucose metabolism, cancer cells also
exhibit fundamental alterations in amino acid metabolism that
contribute to tumorigenicity. Metabolic flux analysis using either
NMR or mass spectrometry is a powerful approach toward
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Figure 1. Dysregulated Metabolic Pathways in Cancer Cells Identified Thus Far
The metabolic pathways that sustain the proliferative nature of cancer cells are very much the same pathways that constitute the metabolism of normal cells.
However, cancer cells are able to aberrantly rewiremany of these normal pathways tomeet their excessive needs for growth and proliferation. In the figure above,
we see that pathways that have been revealed to be essential in cancer cells (shown in red) are pathways that are fundamentally important for the synthesis of
biological macromolecules, antioxidants, and signaling molecules that facilitate cellular growth, survival, and progression. The ‘‘Warburg effect,’’ the preferential
shunting of pyruvate to lactate under conditions of normoxia, is facilitated by the switch from the M1 splice isoform of pyruvate kinase to the M2 splice isoform,
which is in general less active due to several modes of regulation on PKM2 activity in the form of protein-protein interactions or posttranslational modifications,
which all collectively inhibit PKM2 activity (Anastasiou et al., 2011; Christofk et al., 2008b; Hitosugi et al., 2009; Lv et al., 2011). The slow nature of this M2 splice
isoform allows for the buildup of upstream glycolytic intermediates rather than favoring the flux of glycolytic carbon through the TCA cycle. Two of the important
upstream glycolytic intermediates that are essential for synthesizing necessary biological macromolecules are glucose-6-phosphate (G6P) and 3-phospho-
glycerate (3PG). The three-step formation of Ribose-5-phosphate (R5P) via 6-phosphogluconolactone (6-PGL) and 6-phosphogluconate (6-PG) involves the
production of reducing equivalent in the form of NADPH, which in turn can be used as the primary reducing power in the production of GSH from its oxidized
precursor glutathione disulfide (GSSG) (Anastasiou et al., 2011). It was also discovered that a significant portion of glycolytic carbon is diverted toward serine and
glycine biosynthesis by phoshphoglycerate dehydrogenase (PHGDH), which catalyzes the conversion of 3-PG to phosphopyruvate. Phosphopyruvate is then
converted to phosphoserine, concurrently with the anaplerotic generation of a-ketoglutarate by glutamine, to supply the TCA cycle (Locasale et al., 2011a;
Possemato et al., 2011). Glutaminolysis-derived a-ketoglutarate provides reducing power in the form of NAPDH and regenerates oxaloacetate (OAA) to form
citrate, both of which are necessary for the production of fatty acids by fatty acid synthase (FASN) (DeBerardinis et al., 2007; Metallo et al., 2012). Under hypoxia
or mitochondrial dysfunction, a-ketoglutarate can also undergo reductive carboxylation to isocitrate and then to citrate to support lipogenesis (Mullen et al.,
2012). Upon hypoxia or if IDH1 or IDH2 is mutated, these enzymes can also form the oncometabolite 2-hydroxyglutarate (2-HG) (Dang et al., 2009; Wise et al.,
2011). Upon synthesis of fatty acids and esterification onto phospholipids or triglycerides, these esterified lipids are mobilized through lipolytic processes
involving enzymes such as monoacylglycerol lipase (MAGL), which can lead to the formation of oncogenic lipid signaling molecules including lysophosphatidic
acid (LPA) and prostaglandins (Nomura et al., 2010b). Fatty acids can also arise from extracellular sources by hydrolysis of triglycerides by lipoprotein lipase (LPL).
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Figure 2. Discovering PKM2 as a Phosphopeptide Binding Protein
using Quantiative Proteomics
Christofk et al. labeled HeLa cells with heavy isotopic 13C-lysine and
13C-arginine or normal isotopic 12C-lysine and 12C-arginine. The heavy labeled
cell lysates were collected and flowed over a phosphorylated peptide library,
while the light labeled lysates were flowed over an unphosphorylated peptide
library. The eluents were then digested and subsequently analyzed by LC/MS-
MS. By identifying proteins that exhibited a high ratio of heavy to light label,
phosphoproteins could be identified. One such protein that exhibited
a particularly high SILAC heavy to light ratio was pyruvate kinase M2 (PKM2)
(Christofk et al., 2008b).
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incorporation of 13C-labeled metabolites arising from 13C-glu-
cose or 13C-glutamine treatment of cells (Figure 3). The metabo-
lism of glutamine to lactate through ‘‘glutaminolysis’’ has been568 Cell Metabolism 16, November 7, 2012 ª2012 Elsevier Inc.shown to be a particularly important anaplerotic driving force
for cancer cell proliferation (DeBerardinis et al., 2008a). Anaple-
rosis refers to the replenishment of mitochondrial citric acid
carbon pool. Glutamine can drive anaplerosis by providing the
mitochondria with precursors for the synthesis of nucleotides,
amino acids, and lipids. DeBerardinis et al. utilized 13C-labeled
nutrients (e.g., 13C-glucose or 13C-glutamine) coupled with 13C
NMRspectroscopy as amethod to selectively enrichmetabolites
in real time, allowing for the measurement of metabolic fluxes,
toward understanding how biochemical pathways become re-
wired in cancer. Through these studies, DeBerardinis et al. found
that cancer cells utilize the tricarboxylic acid (TCA) cycle primarily
to generate building blocks, in particular citrate, which is ex-
ported out of the mitochrondria to provide acetyl CoA for fatty
acid and phospholipid biosynthesis (DeBerardinis et al., 2007)
(Figures 1 and3). They also found that glutamine-dependent ana-
plerosis, the process of glutamine replenishing TCA cycle inter-
mediates, satisfied the large cellular demand for reducing power
(NAPDHgeneration) and oxaloacetate renewal (via conversion of
glutamine to a-ketoglutarate) that is necessary for continued (De-
Berardinis et al., 2007) fatty acid synthesis and TCA flux.
Another route for the production of a-ketoglutarate within the
cells is via a reaction catalyzed by the TCA cycle enzyme isoci-
trate dehydrogenase1 (IDH1). IDH1 catalyzes the oxidative
decarboxylation of isocitrate to a-ketoglutarate with concomi-
tant reduction of NADP+ to NADPH. A genome-wide analysis
consisting of sequencing protein-coding genes and RNA se-
quencing of glioma and acute myeloid leukemia patients
identified mutations in the active site of the enzyme IDH1 as
a common feature of a major subset of low-grade gliomas and
secondary glioblastomas and leukemic cancers (Mardis et al.,
2009; Parsons et al., 2008). Thesemutations were found to occur
at a single amino acid residue of IDH1, arginine 132, which is
most commonly mutated to histidine. In an effort to understand
the effects of such a mutation on the cellular metabolome,
Dang et al. stably transfected U87MG glioblastoma cells with
both myc-tagged wild-type IDH1 and R132 mutant IDH1 and
compared the metabolomes of these cells using an untargeted
liquid chromatography/mass spectrometry (LC/MS)-based un-
targeted metabolomic profiling approach, which allows for an
unbiased comparison of metabolites altered between two
groups. The authors identified a novel oncometabolite 2-hydrox-
yglurarate (2-HG) that was dramatically increased in cells that
contained this R132 mutation in IDH1 (Dang et al., 2009). Sur-
prisingly, while the wild-type IDH1 produced a-ketoglutarate
and NADPH, in vitro assays revealed that the R132 mutant
IDH1 consumed NADPH and reduced a-ketoglutarate to 2-HG
(Dang et al., 2009) (Figure 1). These studies provided the first
evidence for a mutated enzyme in cancer conferring not only
a loss of endogenous function but also a neomorphic function
to yield an unforeseen metabolite, and underscored the utility
of using unbiased and untargeted metabolomic approaches to
study cancer metabolism.
Further metabolomic profiling by Reitman et al. revealed that
both mutation in IDH1 and separate treatment with 2-HG re-
sulted in a host of downstream metabolic changes including
changes in amino acids, GSH metabolites, choline derivatives,
and TCA cycle intermediates (Reitman et al., 2011). Specifically,
using targeted LC-MS/MS they also found that the N-acetylated
[   C]glucose
pyruvate
citrateOAA
malate
fumarate
succinate
succinyl-CoA
α-KG
isocitrate
citrate
acetyl coA fatty acidsmitochondria
TCA cycle
13
pyruvate
acetyl CoA
[   C] glucose carbons13
[   C] glutamine carbons13
control cancer cell
hypoxic or
mitochondrial dysfunction
cancer cell
metabolic flux analysis
[   C]glucose13
[   C]glutamine13
or+
mass spectrometry
or NMR-based
metabolic flux analysis
α-KG
OAA
citrate
citrate
acetyl coA fatty acids
OAA
+
+
isocitrate
citrate
citrate
control cancer cell
hypoxic or
mitochondrial dysfunction
cancer cell
control cancer cell
hypoxic or
mitochondrial dysfunction
cancer cell showing
reductive carboxylation
[   C]glutamine13
A
B hypoxia or mitochondrial dysfunction promotes IDH-dependent
reductive carboxylation of α−KG to citrate
isocitrate
Figure 3. Metabolic Flux Analysis Reveals Dysregulated Cancer Cell Metabolism under Hypoxia or Mitochondrial Dysfunction
(A) Recent studies have performed metabolic flux analysis on cancer cells labeled with [13C]glucose or [13C]glutamine to dissect dysregulated metabolism of
cancer cells exposed to hypoxia or mitochondrial dysfunction.
(B) These studies revealed that cancer cells under normoxia can form citrate through both glycolysis (bottom row of labeled carbons in TCA cycle) and gluta-
minolysis (top row of labeled carbons in TCA cycle). Upon hypoxia or mitochondrial dysfunction, cancer cells undergo a metabolic switch in citrate which is
produced through glutamine-dependent reductive carboxylation of a-ketoglutarate (a-KG) to form isocitrate via IDH1 or IDH2 and then to citrate to support de
novo lipogenesis (blue arrows). Shown in the figure are [13C]-labeled carbons arising either from glucose (in green) or glutamine (in red) after one pass through the
TCA cycle. Carbon atoms arising from CO2 are labeled as black dots.
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tides in the brain) were significantly lowered in cells containing
a mutated IDH1 (Reitman et al., 2011).
In addition to its role in eliciting direct metabolic changes,
IDH1-derived 2-HG has also recently been shown to play an
epigenetic role in cancer, primarily through an increase in CpG
island methylation. Using a large-scale genome-wide analysis
of DNA methylation, Noushmehr et al. profiled promoter DNA
methylation alterations in 272 glioblastoma tumors and found
that a distinct subset of these glioblastomas were positive for
this CpG island methylator phenotype (G-CIMP) (Noushmehr
et al., 2010). Strikingly, these G-CIMP-positive samples were
tightly correlated with mutations in IDH1. Figueroa et al. further
extended this correlation between IDH1 mutation and DNA
methylation to other cancers types, as they showed that IDH1/
IDH2 mutant AML is associated with more extensive promoter
hypermethylation compared to other AML subtypes (Figueroa
et al., 2010). The mechanism underlying the role of 2-HG in
driving DNA methylation is still unclear; however, recent evi-
dence from Xu et al. has shown that 2-HG can act as a com-
petitive inhibitor of a-ketoglutarate-dependent demethylases,
including histone demethylases and the TET family of 5-methyl-
cytosine hydroxylases, thereby explaining this correlation
between IDH1-derived 2-HG and CpG island hypermethylation
(Xu et al., 2011). Recent studies have also shown that mutations
in IDH1 are sufficient to establish the glioma hypermethylator
phenotype, showing that introduction of mutant IDH1 into
primary human astrocytes alters specific histone marks, induces
extensive DNA hypermethylation, and reshapes the methylome
in a similar manner to the changes observed in glioma CpG
island methylator phenotype-positive lower-grade gliomas (Tur-
can et al., 2012). Intriguingly, Lu et al. also showed that introduc-
tion of mutant IDH into immortalized astroyctes resulted in
progressive accumulation of histone methylation. They also
showed that 2-HG was associated with repression of the
inducible expression of lineage-specific differentiation genes in
adipocytes and blocked differentiation through inhibiting H3K9
demethylase KDM4C, and that genetic knockdown of this
enzyme was sufficient to block differentiation (Lu et al., 2012).
Interestingly, recent studies have shown that under hypoxia
or mitochondrial dysfunction, cancer cells undergo a switch in
which citrate, an important lipogenic precursor, is produced not
from glycolytic carbon, but primarily from glutamine via reductive
carboxylation of a-ketoglutarate to isocitrate via IDH1 or IDH2
(Metallo et al., 2012; Mullen et al., 2012; Scott et al., 2011; Wise
et al., 2011). These studies mapped this reductive carboxylation
pathway using metabolic flux analysis measuring incorporation
of 13C-labeled carbons arising from 13C-glucose or 13C-gluta-
mine labeling in cells by mass spectrometry or NMR. These
studies also showed that knocking down IDH2 impairs cell prolif-
eration (Wise et al., 2011). Furthermore, Metallo et al. showed
that cancer cells deficient in the von Hippel-Lindau (VHL) tumor
suppressor, a protein frequently lost in renal cell carcinoma,
preferentially utilize reductive glutamine metabolism for lipogen-
esis even under normoxic conditions. In a separate study, Wise
et al. intriguingly showed that 2-HG, originally thought to arise
only frommutated neomorphic IDH, can in fact be formed in cells
possessing wild-type IDH1 and IDH2, also through reductive
metabolism by IDH2 in the mitochondria (Wise et al., 2011).570 Cell Metabolism 16, November 7, 2012 ª2012 Elsevier Inc.Collectively, mass spectrometry and NMR-based metabolo-
mic studies have provided valuable insights into how cancer
cells undergo a metabolic switch that consists of glutamine-
dependent anaplerotic pathways that can convert a-ketogluta-
rate through either wild-type or mutated IDH1 and IDH2 to
isocitrate through reductive mechanisms, which in turn can
support lipid biosynthesis to fuel cancer cell proliferation. Untar-
geted and unbiased metabolomic approaches have also un-
covered neomorphic roles associated with mutant IDH, which
generates the oncometabolite 2-HG. Subsequent studies have
shown this oncometabolite to be demethylase inhibitor, leading
to epigentic changes that may drive cancer.
Recent experimental approaches have revealed that many
other amino acid metabolic pathways are also dysregulated
in cancer and contribute to cancer aggressiveness. Locasale
et al. found that in some cancer cells a relatively large amount
of glycolytic carbon is diverted into serine and glycine metabo-
lism (Locasale et al., 2011a) (Figure 1). They showed this using
two independent metabolomic approaches. They first used
sensitivity-enhanced nuclear magnetic resonance (NMR)-based
two-dimensional heteronuclear single-quantum correlation
spectroscopy (HSQC) to quantify steady-state levels of glu-
cose-derived metabolites in HEK293T cells following 24 hr of
labeling with 13C-glucose. While, as expected, lactate levels
were extremely high, surprisingly, the glycolytic flux toward
glycine was also equally high. In the second experimental
approach, using targeted LC-MS/MS-based measurements of
metabolites, they found that a substantial portion of 13C-glucose
was diverted from 3-phosphoglycerate to the serine and glycine
biosynthetic pathways, on par with incorporation of glucose
carbons into nucleotides. The first committed step in this
pathway is the oxidation of the glycolytic intermediate 3-phos-
phoglycerate to 3-phosphohydroxypyruvate by the enzyme
phosphoglycerate dehydrogenase (PHGDH). Using a functional
genomics approach, Locasale identified PHGDH as a frequently
amplified gene in a pooled analysis of somatic copy number
alterations across 3,131 cancer samples, most notably in mela-
noma cells (Locasale et al., 2011a). Concurrent with the study
from Locasale et al., Possemato et al. devised an elegant nega-
tive-selection in vivo RNAi genomics screenwhich also identified
PHGDH as an important metabolic pathway in tumorigenesis
and cell proliferation (Possemato et al., 2011) (Figure 4). They
first crossreferenced maps of metabolic pathways with the
KEGG database to compile a comprehensive list of 2,752 genes
encoding all known humanmetabolic enzymes and transporters.
From this list, genes were prioritized based on their association
with cancer and stem cell-like properties to a set of 133 meta-
bolic enzyme and transporter genes. They then screened for
RNA interference oligonucleotides for each of these 133 genes
that become depleted during breast tumor formation in mice.
Sixteen hits were identified, including PHDGH. They further
showed that PHGDH is in a genomic region of recurrent copy
number gain in breast cancer and that PHGDH protein levels
are elevated in 70% of estrogen receptor (ER)-negative breast
cancers. They further demonstrated that knocking downPHGDH
reduces cell proliferation in breast cancer cells. Through mea-
surement of steady-state levels and incorporation of isotopic
13C-glutamine in cells followed by targeted LC/MS analysis,
the authors also found that PHGDH knockdown results in
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Figure 4. Functional Genomic Approach to Discover PHGDH as an
Important Metabolic Enzyme in Cancer
Possemato et al. used an elegant negative selection in vivo RNAi screen to
identify metabolic enzymes necessary to support breast tumorigenesis. A
prioritized list of 133 metabolic enzymes and metabolite-transport genes was
individually knocked down by shRNA lentiviral constructs in MCF10a cells,
combined together, and collectively injected into mice. Upon tumor formation,
the resultant cancers were screened by sequencing efforts to identify genes,
for which the knockdown was selected against. From this functional genomic
screen, a total of 16 genes were identified, one of which was PHGDH, involved
in serine and glycine biosynthesis (Possemato et al., 2011).
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anaplerosis of glutamine to a-ketoglutarate (Possemato et al.,
2011). They found that the serine synthesis pathway is respon-
sible for approximately 50% of the net conversion of glutamine
to a-ketoglutarate. Collectively, these two parallel studies using
innovative genomic and metabolomic tools show how PHGDH
promotes cancer pathogenicity by diverting glycolytic flux to
serine and glycine biosynthetic pathways.
Dysregulated Lipid Metabolism that Supports Cellular
Membrane Biosynthesis and Oncogenic Lipid Signaling
Pathways
Dysregulated lipid metabolism and heightened de novo lipogen-
esis are established hallmarks of cancer (Menendez and Lupu,2007; Wymann and Schneiter, 2008). Tumor cells synthesize
fatty acids for the purpose of membrane synthesis as well as
for the generation of lipid signaling molecules to fuel cell prolifer-
ation and cancer malignancy (Menendez and Lupu, 2007). These
lipid signaling pathways that are critically important in driving
almost every aspect of cancer progression include phosphatidyl
inositol, lysophosphatidic acid (LPA), sphingosine-1-phosphate,
and prostaglandin signaling pathways (Engelman et al., 2006;
Mills and Moolenaar, 2003; Pyne and Pyne, 2010; Wang and Du-
bois, 2010).
In 1994, Kuhajda et al. discovered fatty acid synthase (FASN)
as an oncogenic protein that was found in tumor cells frombreast
cancer patients with markedly poorer prognosis (Kuhajda et al.,
1994). Since this time, understanding dysregulated lipid metab-
olism in cancer cells has gained considerable interest. Several
studies have shown that genetic and pharmacological ablation
of FASN leads to impairments in cancer pathogenicity, specifi-
cally cell-cycle arrest and apoptosis (Menendez and Lupu,
2007). Several mechanisms for FASN inhibition-based cytotox-
icity have been proposed including phospholipid depletion, alter-
ations in lipid rafts, inhibition in DNA replication, malonyl CoA
buildup and associated toxicity, and inhibition of antiapoptotic
proteins such as Akt. These studies have been reviewed pre-
viously and will not be discussed further in this perspective
(Menendez and Lupu, 2007). Common FASN inhibitors that
have been used to study the role of FASN in cancer include cer-
ulenin and its derivative C75, epigallocatechin-3-gallate, triclo-
san, and orlistat, which target different regions of the FASN
complex and elicit apoptotic cell death in cancer cells (Menendez
and Lupu, 2007). However, none of these inhibitors are likely very
selective for FASN and are not suitable for clinical development
(Va´zquez et al., 2008). Newer pharmacological inhibitors of
FASN that are significantly more potent and selective have arisen
from the pharmaceutical industry, including GSK837149A from
GlaxoSmithKline, identified from an impurity found in an active
hit from a high-throughput screen utilizing an NAPDH consump-
tion assay (Va´zquez et al., 2008). Merck has also recently identi-
fied the broad-spectrum antibiotic platensimycin as a selective
mammalian fatty acid synthase inhibitor (Wu et al., 2011).
While the de novo synthesis of lipids has clearly been shown to
be essential to conferring cancer malignancy, the mobilization of
esterified lipids is also necessary to remodel cellular lipids into
protumorigenic lipid signaling molecules (Nomura et al., 2010b;
Wymann and Schneiter, 2008). A recent study utilized a che-
moproteomic platform termed activity-based protein profiling
(ABPP) to identify monoacylglycerol lipase (MAGL) as a highly
expressed serine hydrolase inmultiple human aggressive cancer
cells and primary tumors (Nomura et al., 2010b, 2011) (Figure 5).
ABPP uses active-site-directed chemical probes to interrogate
the functional state of large numbers of enzymes directly in
native complex proteomes (Nomura et al., 2010a). Because
activity-based probes label the active sites of their enzyme
targets, they can form the basis for a competitive screen for
enzyme inhibitors. Long et al. used this approach to develop a
highly potent and selective inhibitor of MAGL, JZL184, previous
to this study (Long et al., 2009). Pharmacological and genetic
ablation of MAGL in aggressive cancer cells lines using JZL184
or RNA interference resulted in impairments in cancer cell
aggressiveness and tumorigenicity, while the overexpressionCell Metabolism 16, November 7, 2012 ª2012 Elsevier Inc. 571
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(A) ABPP uses active site-directed probes to assess the functional state of large numbers of enzymes directly in complex proteomes (Nomura et al., 2010a).
Activity-based probes (ABPs) consist of a reactive group, a spacer arm, and a detection handle (e.g., fluorophore such as a rhodamine [Rh] or biotin [B]). In
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Reviewof MAGL in nonaggressive cancer enhanced cancer cell
pathogenicity. Using a mass-spectrometry-based untargeted
metabolomics approach termed discovery metabolite profiling
(DMP), the authors then showed that MAGL blockade leads to
elevations in the antitumorigenic endocannabinoid signaling lipid
2-arachidonoylglycerol and reductions in free fatty acid (FFA)
levels in aggressive cancer cells, which in turn reduce the
downstream levels of protumorigenic signaling lipids such as
LPA and prostaglandins (Nomura et al., 2011; Nomura et al.,
2010b) (Figures 1 and 5). The pathogenicity deficits observed
by MAGL knockdown were rescued by addition of fatty acids,
LPA, or PGE2 in vitro or a high-fat diet in vivo. These results taken
together demonstrate how cancer cells can co-opt a lipolytic
enzyme to translate their lipogenic state into an array of protu-
morigenic signals.
Consistent with Nomura et al.’s findings that an increase in die-
tary fat intake could potentially drive cancer cell pathogenesis,
Kuemmerle et al. were able to demonstrate that some cancer
cells also rely on the presence of another lipolytic enzyme, lipo-
protein lipase (LPL), to acquire fatty acids from circulating dietary
triglycerides, thereby fueling their growth and proliferation. Using
gene expression profiling methods, Kuemmerle et al. revealed
that select breast and prostate cancer cells express high levels
of both LPL and the fatty acid transporter CD36 (Kuemmerle
et al., 2011). In the cells in which there was no substantial
increase in LPL gene expression, they showed, through further
transcriptomic analysis, that these cells maintained extremely
high expression of genes that promote endogenous fatty acid
synthesis,most notably FASN. Furthermore, upon pharmacolog-
ical blockade of endogenous fatty acid synthesis, exogenous
delivery of LPL along with triglyceride-rich lipoprotein particles
served to rescue the malignant phenotype that was previously
lost upon inhibition of endogenous fatty acid production (Kuem-
merle et al., 2011) (Figure 1). Nieman et al. recently discovered
that primary human omental adipocytes promote homing,migra-
tion, and invasion of ovarian cancer cells, through direct transfer
of lipids from adipocytes to ovarian cancer cells to promote
tumor growth. Through protein array profiling, the authors found
an upregulation in fatty acid binding protein 4 (FABP4) in omental
metastases as compared to primary ovarian tumors, and that
FABP4 deficiency substantially impaired ovarian tumor metas-
tasis in mice (Nieman et al., 2011). Taken together, these results
indicate that cancer cellsmust increase their production of global
fatty acids in one of three ways: endogenous production (via
FASN), release of esterified fatty acids (via MAGL), or release
and absorption of fatty acids from dietary sources (via LPL and
FABP4).a typical ABPP experiment, a proteome is reacted with the activity-based probe a
(above), or by avidin enrichment, on-bead tryptic digest, and identification and qu
(MudPIT) for biotinylated-ABPs (below) (Nomura et al., 2010a). Through ABPP a
rophosphonate (FP)-Rh or FP-biotin, KIAA1363 andMAGLwere identified as upre
et al., 2002; Nomura et al., 2010b).
(B) ABPP can also be used in a competitive format to assess potency and selectivi
enzyme inhibition will be read out by loss of fluorescence on a SDS-PAGE gel (us
abiotintylated-ABP).CompetitiveABPPwasused todevelopselective inhibitorsof
(C) With selective inhibitors in hand, the metabolic roles of KIAA1363 and MAGL
which metabolomes were extracted and analyzed by LC-MS, broadly scanning f
data that arise from untargeted metabolomic analysis, powerful software tool XC
(Smith et al., 2006) which aligns, quantifies, and statistically ranks ions that are a
annotate KIAA1363 and MAGL as enzymes that regulate ether lipid and fatty aciIn addition to fatty acid-derived glycerolipids, ether lipid
metabolism has also been known to be dysregulated in cancers
since the pioneering work performed in the 1960s by Snyder
and Wood (Snyder and Wood, 1969; Wood and Snyder, 1967),
but the metabolic pathways that drive this metabolic transition
were not well understood. Studies utilizing ABPP platforms
identified the serine hydrolase KIAA1363 as one such driver
of ether lipid metabolism that is upregulated across multiple
human aggressive cancer cells and primary tumors (Chiang
et al., 2006; Jessani et al., 2005). Several potent and selective
pharmacological carbamate inhibitors of KIAA1363 have been
developed through competitive ABPP approaches, such as
AS115 and JW480, as well as an activity-based imaging probe
JW576, which are all based off of the carbamate scaffold (Chiang
et al., 2006; Chang et al., 2011a, 2011b). Both pharmacological
and genetic blockade of KIAA1363 have been shown to impair
cancer cellmigration, invasion, and in vivo tumorigenicity through
lowering ether lipids and oncogenic signaling lipids such as alkyl
LPA (Chiang et al., 2006; Chang et al., 2011b) (Figure 5).
Challenges in the Field of (Cancer) Metabolism
The field of cancer metabolism has thus far focused on major
commonly known biochemical pathways, such as glycolysis,
TCA cycle, fatty acid synthesis, and amino acid metabolism
(Lunt and Vander Heiden, 2011). While this has been critical for
delineating the foundational structure of altered metabolism in
cancer, looking toward the future we need to expand our inves-
tigations and technologies tomore comprehensively encompass
different aspects of metabolism. This endeavor, however, is
hindered by our incomplete understanding of the metabolic
pathways that operate in normal human cells, let alone in
cancerous ones. We also lack pharmacological tools to interro-
gate even very well-understood biochemical pathways, as
evidenced by a dearth of specific inhibitors for enzymes in
glycolysis or TCA cycle. Metabolic pathways are likely quite
plastic and adaptable in cancer cells, so we view the develop-
ment of selective chemical probes to perturb these networks
in a rapid and temporally controlled manner as an important
complementary approach to gene knockouts or knockdowns,
which typically create models of prolonged target disruption.
Let’s consider a hypothetical situation that underscores the
technical challenges that remain for researchers interested in
understanding and controlling cancer metabolism. Presume
that one finds through a genome- or proteome-wide search a
poorly characterized enzyme that highly correlated with cancer;
how does one gain understanding of the biochemical function
that this enzyme performs in tumor cells and integrate its activitynd readout either by fluorescence on a 1D-SDS-PAGE gel for rhodamine-ABPs
antification of peptides by Multidimensional Protein Identification Technology
nalysis of the serine hydrolase proteome with the serine hydrolase ABP fluo-
gulated in multiple human aggressive cancer cells and primary tumors (Jessani
ty of inhibitors in complex proteomes. Inhibitors can compete with the ABP and
ing a rhodamine-ABP) or loss of spectral counts by mass spectrometry (using
KIAA1363andMAGL (Chianget al., 2006;Changet al., 2011b; Longet al., 2009).
were elucidated using untargeted LC-MS-based metabolomic approaches in
or metabolites across a large mass range. To complement the large amount of
MS was used for quantitation and identification of ions within LC/MS data sets
ltered between two sets of metabolomic data. This methodology was used to
d networks, respectively (Chiang et al., 2006; Nomura et al., 2010b).
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pathogenesis? In this review, we have presented instances
where advanced proteomic and metabolomic approaches
have achieved this goal. However, the metabolome rivals, if
not surpasses, the genome and proteome in terms of its physi-
cochemical content and complexity. As such, current analytical
technologies, even when used in combination, likely do not
approach providing a complete picture of the metabolome.
Here, improvements in methods for metabolite enrichment,
separation, and identification, as well as continued advances
in MS and NMR platforms, should enable researchers to delve
deeper and deeper into the highly diversified metabolomic land-
scape of cells and tissues.
If a comprehensive and global understanding of metabolic
pathways in cancer is to be achieved, the insights gained from
metabolomic mapping of enzyme functions in cancer must be
coupled to the assembly of biochemical reactions into pathways
and larger metabolic networks. Essential to this process is
mapping the metabolic flux through these pathways and
networks, not only in situ in cells, but also in living systems or
in live tumors in human patients and modeling these fluxes to
identify critical nodes for therapeutic intervention (Wahrheit
et al., 2011). There are indeed powerful strategies for measuring
both in situ and in vivo metabolic flux using isotopic tracers,
including monitoring 13C-labeled substrates and their metabolic
fates (Zamboni, 2011) or tracing D2O heavy water (Hellerstein
and Murphy, 2004) in lipid, nucleic acid, and amino acid metab-
olism.While single isotopic tracers are an extremely valuable tool
that can be used to probe metabolic networks, the application of
multiple tracers simultaneously has provided an even more
thorough understanding of metabolic flux. To this end, a recent
paper by Walther et al. has elegantly elucidated a method that
allows researchers to determine the optimal tracer combination
for a particular metabolic pathway (Walther et al., 2012). More
recently, Hiller et al. have developed a new methodological
approach to trace stable isotopes in nontargeted metabolomics
data (Hiller et al., 2011). These endeavors will have to be im-
proved and further implemented in the study of cancer metabo-
lism with better isotopic or chemical labeling strategies coupled
with improvements in imaging, magnetic resonance, mass-
spectrometry-based platforms, and modeling tools to better
dissect cancer metabolism and use these approaches to diag-
nose and treat cancer patients.
Beyond technical challenges, there are also conceptual
advances that must bemade. Much of the field of cancer metab-
olism, for instance, has focused to date on pathways that are
altered during the transformation process that initiates cancer.
Less is understood about the metabolism that drives specific
stages of tumor progression, malignancy, and eventually metas-
tasis and drug resistance. It is possible that even the same
general metabolic pathway may contribute in different ways to
individual stages of cancer. Take as an example lipogenesis.
FASN is highly upregulated during the transformation process
and contributes substantially to proliferation and survival, pre-
sumably by generating cellular membranes required for cell
division, as well as possibly substrate for energy production
by fatty acid oxidation. However, on its own, FASN does not
appear to produce lipid changes that promote high malignancy
(Migita et al., 2009). Upregulation of MAGL, on top of a high574 Cell Metabolism 16, November 7, 2012 ª2012 Elsevier Inc.FASN background, on the other hand, may promote this
conversion to an aggressive state by liberating fatty acids for
the biosynthesis of promigratory signaling lipids (e.g., lysophos-
pholipids, eicosanoids). Only by examining cancer cells (or
tumors) at different stages of disease progression, as opposed
to more classical comparisons of normal and transformed
cells, can such examples of coadapting metabolic pathways
be uncovered.
Recent work also suggests that malignant progression of
cancer is accompanied by an increased proportion of cancer
stem/precursor cells (CSCs) within the tumor (Pece et al.,
2010) and that activation of the epithelial-to-mesenchymal tran-
sition (EMT) is associated with CSC properties, including expres-
sion of the stem cell-associated antigenic profile (e.g., CD44+/
CD24-/low for breast cancer), self-renewal capabilities, resis-
tance to conventional therapies, cancer aggressiveness, and
poor clinical outcome for multiple tumor types (Chaffer and
Weinberg, 2011; Gupta et al., 2009b; Pece et al., 2010; Sabbah
et al., 2008). Several studies have linked EMT directly to CSCs
and aggressive properties of cancer (Cordenonsi et al., 2011;
Gupta et al., 2009a; Mani et al., 2008) and have shown that
CSCs or cells that have undergone EMT are highly resistant to
traditional cancer therapies(Barr et al., 2008; Buck et al., 2008;
Zielske et al., 2010), indicating that current therapeutic strategies
preferentially target the non-CSC population. Despite the poten-
tial importance of this CSC population, the metabolic alterations
that underlie EMT or CSCs remain poorly understood, although
emerging data suggest that human cancer cell lines possessing
EMT/stem-like features also display a unique set of metabolic
enzymes (Nomura et al., 2011). Disrupting these pathways with
small molecule inhibitors or RNA-interference probes should
inform on their specific contributions to the biochemistry and
malignant properties of CSCs.
In addition to identifying dysregulated metabolic pathways
that underlie cancer initiation and progression, understanding
the mechanism by which these pathways become dysregulated
will also be essential for the diagnosis and treatment of cancer
patients. Identifying the upstream ‘‘master regulator’’ may pro-
vide nodes that can be targeted to shut down entire metabolic
programs that drive cancer. For example, a recent study by
Gaglio et al. showed oncogenic Kras to be essential for the
metabolic reprogramming of cancer cells by enhancing glyco-
lytic activity, decreasing TCA flux, and increasing the utilization
of glucose for anabolic means (Gaglio et al., 2011). More
recently, a study by Ying et al. showed that oncogenic Kras
maintains pacreatic tumors through regulation of anabolic glu-
cose metabolism, channeling glucose intermediates into both
the hexosamine biosynthesis and pentose phosphate pathways
(Ying et al., 2012). PHGDH copy number appears to be highly
amplified in human cancers, which accounts for its subsequent
metabolic and oncogenic effects (Locasale et al., 2011b).
However, themechanism behind what drives other dysregulated
metabolic pathways is not as well understood, and some of
these pathways are likely turned on by upstream signaling or
posttranslational mechanisms.
Beyond profiling metabolic enzymes implicated in transfor-
mation, stemness, malignancy, and metastasis, it still remains
unclear in any of these instances whether the dyregulated
enzymes, when pharmacologically targeted, will have a strong
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Reviewenough effect on disease progression to be therapeutic. Drug
programs that target a metabolic enzyme would benefit from
identifying genetically defined cancer subtypes (or resistance
phenotypes) that are mechanistically tied to the disrupted path-
ways, so that one can properly select patients for therapeutic
testing. Such mechanistic links, in most cases, have yet to be
established. Drugs that target cancer metabolism will also likely
have to be combinedwith current chemotherapeutic regimens to
exhibit or maximize therapeutic efficacy. The optimal combina-
tion of these drugs or whether we can reduce current chemo-
therapy dosing regimens when combined together with cancer
metabolism-based therapy is not well understood. For malig-
nancy-related enzymes, the problem may even more chal-
lenging, since they may contribute principally to processes like
metastasis, which are more difficult to monitor preclinically and
clinically compared to simple tumor growth.Conclusions
Ever since Warburg first proposed that cancer may be a dis-
ease defined by aberrant metabolism, scientists have sought
to define the specific biochemical pathways that enable previ-
ously normal cells to take on a deviant tumorigenic state. This
review has highlighted many of the unique discovery platforms
and global profiling approaches that are leading the way to
identify new biochemical nodes that contribute to cancer devel-
opment and malignancy. These include multiple inhibitory con-
trols on glycolysis (e.g., PKM2) that divert flux of glycolytic
carbons into anaplerotic pathways for generation of biosynthetic
precursors, such as amino acids through PHGDH, or redox
potential through the pentose phosphate pathway. Also in-
cluded is a fundamental rewiring of cancer cells to exert height-
ened utilization of other carbon sources such as glutamine to
supply TCA cycle anaplerosis; in certain cases, this occurs
through IDH1/2-mediated reductive carboxylation to generate
intermediates such as citrate that fuel de novo lipogenesis
through FASN. Beyond the synthesis of cellular membrane lipids
required for proliferation, studies have also found that these
lipids are mobilized by distinct enzymatic pathways in cancer
cells (e.g., MAGL, LPL, KIAA1363) to create building blocks
for protumorigenic signaling lipids and for use as an energy
source. Quite intriguingly, certain enzymes can even acquire
neomorphic activities through mutation, such as mutant IDH,
which generate novel oncogenic biomolecules that have wide-
spread metabolic and epigenetic consequences. These findings
have arisen out of the integrated utilization of genomic (deep
genome sequencing and RNA sequencing), proteomic (post-
translational mapping and functional proteomics), and metabo-
lomic (steady-state, targeted/untargeted, and metabolic flux
analysis) approaches. We expect that the continued efforts to
probe biochemical pathways in cancer cells using such large-
scale profiling methods will strengthen our understanding
of dysregulated metabolism in cancer and identify potential
avenues for therapeutic intervention.ACKNOWLEDGMENTS
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